GoodRx reports GLP-1 weight-loss pills are emerging, with candidates like orforglipron and oral semaglutide likely to gain FDA approval by 2026.

The Trump administration on Tuesday canceled an additional $450 million in grants for Harvard University, a fresh broadside in the clash between the federal government and the oldest university in ...

CHICAGO, March 17, 2025--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing ...

Table 2 shows data on 14 induced insulin reactions in 14 patients. Thirteen of the 14 patients exhibited the characteristic clinical picture of hypoglycemia before glucagon administration ...

RECENT progress in glucagon research has made this hormone available in high purity ... Prolonged Glucagon Administration in a Case of Hyperinsulinism Due to Disseminated Islet-Cell Carcinoma.

This statutory change has prompted a proposed amendment to Section 136.7 of the NY Commissioner Regulations that provides training requirements for the administration of non-injectable glucagon.

GlucaGen (glucagon) is a prescription brand-name medication. It’s approved by the Food and Drug Administration (FDA) to: GlucaGen HypoKit (a single-dose vial of powder with a single-dose syringe ...

Ogluo/Gvoke is the first prescription, ready-to-use, pre-mixed and pre-measured glucagon injection. It was approved by the US Food and Drug Administration (FDA) in September 2019 for use in the US and ...

Xeris said its share of the retail glucagon market is now up to around 16%, and Gvoke prescriptions topped 21,000 for the first time. hypoglycemia Eli Lilly Novo Nordisk U.S. FDA Xeris ...